1405 Article Views
Publication Date: 10 Sep 2007
Journal: Clinical Medicine Insights: Oncology Clinical Medicine: Oncology 2007:1 1-6
Abstract Yoshihito Yokoyama, Bing Xin, Tatsuhiko Shigeto, Masayuki Futagami and Hideki Mizunuma
Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, 5-Zaifu-cho, Hirosaki, 036-8562, Japan.
Abstract: The purpose of this study was to elucidate the possible mechanism that clofibric acid (CA), a peroxisome proliferator-activated receptor α ligand, enhances a suppressive effect of cis-diaminedichloroplatinum (CDDP) on proliferation of the ovarian carcinoma line OVCAR-3. These cells was incubated with 0.5 μM/ml CDDP in the presence or absence of 50 μM CA or incubated with 50 μM CA alone for 72 hr. While treatment with CA alone did not affect proliferation of OVCAR-3 cells, simultaneous treatment with CDDP and CA significantly suppressed proliferation of the cells and significantly induced apoptosis compared to that with CDDP alone. Treatment with CDDP and CA significantly decreased the prostaglandin (PG) E2 level in the medium of the cells compared with treatment with CDDP alone. These results suggest the ability of CA to enhance a suppressive effect of CDDP on proliferation of the ovarian carcinoma cells through reduction of PGE2 level.
Discussion
No comments yet...Be the first to comment.
I had an excellent experience publishing our review article in Clinical Medicine Reviews. The managing editor was very helpful and the process was very timely and transparent.Professor Jonathan A. Bernstein (University of Cincinnati College of Medicine, Division of Immunology, Allergy Section, Cincinnati, OH, USA) What our authors say
Copyright © 2010 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)